Future for VHL kidney cancer is bright

Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always been difficult to treat. However, a group of researchers led by Dr William G. Kaelin Jr from the Dana-Faber Cancer Institute and Harvard Medical School in America have discovered treatments including immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors for the treatment of VHL-associated RCC. He […]

read more

γ-Glutamyltransferase as a biomarker in patients on nivolumab for metastatic kidney cacner

A protein called γ-glutamyltransferase can predict survival in patients with local and metastatic renal cell carcinoma (RCC); however, in patients treated with immune checkpoint inhibitors, such as nivolumab, this predictive role is unknown. A study to be published in the International Journal of Clinical Oncology aimed to investigate the role of γ-glutamyltransferase as a predictive […]

read more

Cabozantinib plus atezolizumab combination for advanced kidney cancer

In this study, two doses of cabozantinib were tested in combination with atezolizumab for untreated advanced renal cell carcinoma (RCC). Cabozantinib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), while atezolizumab is an immune checkpoint inhibitor.  Two doses of cabozantinib were tested; 40 mg and 60 mg. The data were fairly comparable […]

read more

Everolimus and bevacizumab for advanced papillary kidney cancer

In this phase 2 clinical trial, a combination of everolimus plus bevacizumab was looked at in 37 patients with papillary renal cell carcinoma (RCC). The study showed that the combination was effective and delayed progression of the disease (progression-free survival) on average for 13.7 months. There was a response rate of 35%, and overall survival […]

read more

New survival data for pembrolizumab plus axitinib in advanced kidney cancer

A paper published in The Lancet Oncology this month provides further follow-up data from the KEYNOTE-426 study, which shows superior efficacy of pembrolizumab plus axitinib over sunitinib in patients with untreated advanced renal cell carcinoma (RCC). Eight hundred and sixty one (861) patients were randomly assigned to receive pembrolizumab plus axitinib (432) or sunitinib (429). […]

read more

Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland

The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the avelumab plus axitinib combination for untreated advanced kidney cancer for patients in Scotland. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for avelumab in combination with axitinib for the first-line treatment of patients with advanced or metastatic renal cell carcinoma […]

read more

Quality versus quantity of life with cabozantinib and sunitinib in advanced kidney cancer

Cabozantinib and sunitinib are both drugs that block the development of blood vessels to supply the tumour and are called vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). These drugs are used to treat patients with advanced kidney cancer. Clinical trials have shown that cabozantinib is better at extending survival than sunitinib, giving patients […]

read more

Safety and efficacy of TiNivo in patients with metastatic kidney cancer

Tivozanib is a drug that blocks the blood supply to tumours (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, TKI), and has been shown to be effective and safe in patients with advanced renal cell carcinoma (RCC) when used alone. This study reports the final results from phase 1b/2 clinical trial of tivozanib […]

read more

Association between TKI-induce high blood pressure and outcomes in patients with kidney cancer

In this retrospective study published in Cancer Reports the association between TKI-induced high blood pressure (hypertension) and treatment outcomes was reported. Fifty-two (52) patients with metastatic renal cell carcinoma (RCC) treated with first-line sunitinib, pazopanib, sorafenib, axitinib, or cabozantinib were examined for any association between TKI-induced hypertension and treatment outcomes. The study found that patients […]

read more

Safety and efficacy of apatinib for metastatic kidney cancer

A recent study coming out of China has identified a new oral tyrosine kinase inhibitor (TKI) with promising safety and efficacy for metastatic renal cell carcinoma (RCC). Anti-angiogenic treatments, such as the TKIs sunitinib, pazopanib and axitinib, play an important role in the treatment of metastatic RCC. A new TKI called apatinib targets the vascular […]

read more
Showing 1 to 10 of 79 results
  TOP